Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are there beta-adrenergic receptor response differences between racial groups?

D R Rutledge1

  • 1Department of Pharmacy Practice, College of Pharmacy, Wayne State University, Detroit, MI 48202.

DICP : the Annals of Pharmacotherapy
|July 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applying managed care performance measures in community pharmacy-based outcomes research.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·1999
Same author

Polymorphisms within the atrial natriuretic peptide gene in essential hypertension.

Journal of hypertension·1995
Same author

Polymorphism of the angiotensin I converting enzyme gene in essential hypertensive patients.

Biochemistry and molecular biology international·1995
Same author

Frequencies of the angiotensinogen gene and angiotensin I converting enzyme (ACE) gene polymorphisms in African Americans.

Biochemistry and molecular biology international·1994
Same author

Analysis of two variants of the angiotensinogen gene in essential hypertensive African-Americans.

American journal of hypertension·1994
Same author

Race and hypertension. What is clinically relevant?

Drugs·1994
Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991
Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991
Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991
Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991
Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991
Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991
See all related articles

Racial differences significantly impact beta-adrenergic receptor (BAR) drug responses. Studies show disparities between Black and White individuals, necessitating inclusive clinical trials for antihypertensive medications.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Trials

Background:

  • Beta-adrenergic receptor (BAR) agonists and antagonists are widely prescribed medications.
  • Existing research indicates significant heterogeneity in human pharmacologic responses.
  • Racial disparities in drug efficacy and safety are a growing concern in medical research.

Purpose of the Study:

  • To review the influence of race on beta-adrenergic receptor (BAR) responses.
  • To emphasize the importance of cross-racial studies in drug evaluation.
  • To highlight the need for diverse representation in clinical trials for antihypertensive drugs.

Main Methods:

  • Review of existing literature on BAR responses across different racial groups.
  • Inclusion of data from hypertensive patients and healthy volunteers.

Related Experiment Videos

  • Consideration of in vitro study findings.

    • Main Results:

    • Evidence suggests that race influences BAR pharmacologic responses.
    • Disparities in response are noted, particularly between Black and White populations.
    • Underrepresentation of certain racial groups in clinical trials may skew findings.

    Conclusions:

    • Cross-racial studies are crucial for a comprehensive understanding of BAR effects.
    • Acknowledging racial differences is essential for effective antihypertensive drug development.
    • Ensuring diverse participant representation in clinical trials is vital for equitable healthcare.